The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Shortening the duration of treatment with fixed-duration or MRD-adapted regimens in CLL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the potential of fixed-duration or measurable residual disease (MRD)-adapted therapies in chronic lymphocytic leukemia (CLL). Ongoing clinical trials are exploring combinations of BTK inhibitors, BCL2 antagonists, and antibody-based therapies to achieve maximum efficacy with the shortest treatment duration. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
